Abstract
In this article, we present the case for the existence of a subgroup of patients with osteoarthritis (OA) who experience pain with neuropathic features. Recognizing these patients as a distinct subgroup will allow clinicians to improve the management of their symptoms. We discuss the diagnostic criteria for pain to be classed as neuropathic, then systematically examine the applicability of these criteria to the symptoms, signs and pathology of OA. What are the implications for the preclinical development and clinical use of analgesics for OA? How should existing treatment options be reassessed? Differences in the aetiology of OA and the pharmacological sensitivity of patients with OA pain with neuropathic features, compared with other patients with OA, might explain the frequent negative findings of clinical trials of treatments for symptomatic OA. If the global prevalence of OA pain with neuropathic features is accurately represented by reports from small experimental groups of patients, then a substantial unmet need to tailor diagnosis and therapy for these individuals exists.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Treede, R. D. et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70, 1630–1635 (2008).
Thakur, M., Rahman, W., Hobbs, C., Dickenson, A. & Bennett, D. Characterisation of a peripheral neuropathic component of the rat monoiodoacetate model of osteoarthritis. PLoS ONE 7, e33730 (2012).
Suri, S. et al. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. Ann. Rheum. Dis. 66, 1423–1428 (2007).
Walsh, D. A. et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. Rheumatology (Oxford) 42, 1852–1861 (2010).
Baker, K. et al. Relation of synovitis to knee pain using contrast-enhanced MRIs. Ann. Rheum. Dis. 69, 1779–1783 (2010).
Hill, C. L. et al. Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis. Ann. Rheum. Dis. 66, 1599–1603 (2007).
Schaible, H. Mechanisms of pain in arthritis. Arthritis Res. Ther. 6, 1–2 (2004).
Eitner, A., Pester, J., Nietzsche, S., Hofmann, G. O. & Schaible, H. G. The innervation of synovium of human osteoarthritic joints in comparison with normal rat and sheep synovium. Osteoarthritis Cartilage 21, 1383–1391 (2013).
Hurley, M. V., Scott, D. L., Rees, J. & Newham, D. J. Sensorimotor changes and functional performance in patients with knee osteoarthritis. Ann. Rheum. Dis. 56, 641–648 (1997).
Sharma, L., Pai, Y. C., Holtkamp, K. & Rymer, W. Z. Is knee joint proprioception worse in the arthritic knee versus the unaffected knee in unilateral knee osteoarthritis? Arthritis Rheum. 40, 1518–1525 (1997).
Felson, D. T. et al. The effects of impaired joint position sense on the development and progression of pain and structural damage in knee osteoarthritis. Arthritis Rheum. 61, 1070–1076 (2009).
Wylde, V., Palmer, S., Learmonth, I. D. & Dieppe, P. Somatosensory abnormalities in knee OA. Rheumatology (Oxford) 51, 535–543 (2012).
Shakoor, N. et al. The relationship of vibratory perception with dynamic joint loading, radiographic severity, and pain in knee osteoarthritis. Arthritis Rheum. 64, 181–186 (2011).
Harden, R. N. et al. The osteoarthritis knee model: psychophysical characteristics and putative outcomes. J. Pain 14, 281–289 (2013).
Hendiani, J. A. et al. Mechanical sensation and pain thresholds in patients with chronic arthropathies. J. Pain 4, 203–211 (2003).
Hochman, J. R., Davis, A. M., Elkayam, J., Gagliese, L. & Hawker, G. A. Neuropathic pain symptoms on the modified painDETECT correlate with signs of central sensitization in knee osteoarthritis. Osteoarthritis Cartilage 21, 1236–1242 (2013).
Thakur, M., Dawes, J. M. & McMahon, S. B. Genomics of pain in osteoarthritis. Osteoarthritis Cartilage 21, 1374–1382 (2013).
Street, J., Lenehan, B., Flavin, R., Beale, E. & Murray, P. Do pain referral patterns determine patient outcome after total hip arthroplasty? Acta Orthop. Belg. 71, 540–547 (2005).
Lesher, J. M., Dreyfuss, P., Hager, N., Kaplan, M. & Furman, M. Hip joint pain referral patterns: a descriptive study. Pain Med. 9, 22–25 (2008).
Farrell, M., Gibson, S., McMeeken, J. & Helme, R. Pain and hyperalgesia in osteoarthritis of the hands. J. Rheumatol. 27, 441–447 (2000).
Gwilym, S. E. et al. Psychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patients. Arthritis Rheum. 61, 1226–1234 (2009).
Rahman, W. et al. Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain. Mol. Pain 5, 45 (2009).
O'Neill, J. et al. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol. Rev. 64, 939–971 (2012).
Baron, R., Hans, G. & Dickenson, A. Peripheral input and its importance for central sensitization. Ann. Neurol. 74, 630–636 (2013).
Neogi, T. et al. Central sensitization in knee OA: preliminary results from the MOST study. Osteoarthritis and Cartilage 18 (Suppl. 2), S34 (2010).
Arendt-Nielsen, L. et al. Sensitization in patients with painful knee osteoarthritis. Pain 149, 573–581 (2010).
Imamura, M. et al. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: A controlled analysis. Arthritis Rheum. 59, 1424–1431 (2008).
Graven-Nielsen, T., Wodehouse, T., Langford, R. M., Arendt-Nielsen, L. & Kidd, B. L. Normalisation of widespread hyperesthesia and facilitated spatial summation of deep-tissue pain in knee osteoarthritis patients after knee replacement. Arthritis Rheum. 64, 2907–2916 (2012).
Kosek, E. & Ordeberg, G. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur. J. Pain 4, 229–238 (2000).
Wylde, V., Hewlett, S., Learmonth, I. D. & Dieppe, P. Persistent pain after joint replacement: Prevalence, sensory qualities, and postoperative determinants. Pain 152, 566–572 (2011).
Wylde, V., Palmer, S., Learmonth, I. D. & Dieppe, P. The association between pre-operative pain sensitisation and chronic pain after knee replacement: an exploratory study. Osteoarthritis Cartilage 21, 1253–1256 (2013).
Scanzello, C. R. et al. The influence of synovial inflammation and hyperplasia on symptomatic outcomes up to 2 years post-operatively in patients undergoing partial meniscectomy. Osteoarthritis Cartilage 21, 1392–1399 (2013).
Freynhagen, R., Baron, R., Gockel, U. & Tölle, T. R. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Res. Med. Opin. 22, 1911–1920 (2006).
Bouhassira, D., Lanteri-Minet, M., Attal, N., Laurent, B. & Touboul, C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 136, 380–387 (2008).
Ohtori, S. et al. Existence of a neuropathic pain component in patients with osteoarthritis of the knee. Yonsei Med. J. 53, 801 (2012).
Soni, A. et al. Neuropathic features of joint pain: a community-based study. Arthritis Rheum. 65, 1942–1949 (2013).
Suokas, A. K. et al. Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis. Osteoarthritis Cartilage 20, 1075–1085 (2012).
Maier, C. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): somatosensory abnormalities in 1236 patients with different neuropathic pain syndromes. Pain 150, 439–450 (2010).
Rolke, R. et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain 123, 231–243 (2006).
Finnerup, N. B., Sindrup, S. H. & Jensen, T. S. The evidence for pharmacological treatment of neuropathic pain. Pain 150, 573–581 (2010).
Vonsy, J., Ghandehari, J. & Dickenson, A. Differential analgesic effects of morphine and gabapentin on behavioural measures of pain and disability in a model of osteoarthritis pain in rats. Eur. J. Pain 13, 786–793 (2009).
Beyreuther, B., Callizot, N. & Stohr, T. Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res. Ther. 9, R14 (2007).
Iannetti, G. D. et al. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc. Natl Acad. Sci. USA 102, 18195–18200 (2005).
Vedula, S. S., Bero, L., Scherer, R. W. & Dickersin, K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use. N. Engl. J. Med. 361, 1963–1971 (2009).
Chappell, A. S. et al. Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 146, 253–260 (2009).
Ohtori, S. et al. Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. Yonsei Med. J. 54, 1253–1258 (2013).
Buvanendran, A. et al. Perioperative oral pregabalin reduces chronic pain after total knee arthroplasty: a prospective, randomized, controlled trial. Anesth. Analg. 110, 199–207 (2010).
Steigerwald, I. et al. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain. Clin. Drug Investig. 33, 607–619 (2013).
Hartrick, C., Van Hove, I., Stegmann, J. U., Oh, C. & Upmalis, D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active-and placebo-controlled study. Clin. Ther. 31, 260–271 (2009).
Steigerwald, I. et al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study. Curr. Med. Res. Opin. 28, 911–936 (2012)
Morlion, B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. Curr. Med. Res. Opin. 27, 11–33 (2011).
Acknowledgements
A.H.D. is funded by the Wellcome Trust, London Pain Consortium and Arthritis Research UK. M.T. is funded by the Wellcome Trust. R.B. is funded by the German Federal Ministry of Education and Research (BMBF, NoPain) and GrĂĽnenthal GmbH.
Author information
Authors and Affiliations
Contributions
M.T. wrote the article. M.T., R.B. and A.H.D. researched data for the article, substantially contributed to discussion of the content, and reviewed and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
R.B. declares that he is a member of the speakers' bureau or has received honoraria from Astellas, Bayer-Schering, Boehringer Ingelheim, Desitin, Eisai, Esteve, Genzyme, Grünenthal, Lilly, Medtronic, MSD, Mundipharma, Pfizer, Sanofi Pasteur, and Teva Pharma, and that he has received grant or research support from Genzyme, the German Federal Ministry of Education and Research (BMBF): German Research Network on Neuropathic Pain and NoPain system biology, Grünenthal, the German Research Foundation (DFG) and Pfizer, and he is a member of the IMI “Europain” collaboration, which has industry members, including Astra Zeneca, Boehringer Ingelheim, Grünenthal, Eli Lilly, Esteve, Pfizer, Sanofi Aventis, and UCB-Pharma, and he declares that he has acted as a consultant for Abbvie, Allergan, Astellas, AstraZeneca, Biogenidec, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Genzyme, Grünenthal, Eli Lilly, Medtronic, Merck, Mundipharma, Novartis, Pfizer, Sanofi Pasteur, and UCB BioSciences. A.H.D. declares that he is a member of the speakers' bureau or has received honoraria from Astellas, Grünenthal, Lilly and Pfizer, and that he has received grant or research support from Grünenthal and he is a member of the IMI “Europain” collaboration, which has industry members, including Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Esteve, Grünenthal, Pfizer, Sanofi Aventis and UCB-Pharma, and he declares that he has acted as a consultant for Astellas, Grünenthal and Pfizer. M.T. declares no competing interests.
Rights and permissions
About this article
Cite this article
Thakur, M., Dickenson, A. & Baron, R. Osteoarthritis pain: nociceptive or neuropathic?. Nat Rev Rheumatol 10, 374–380 (2014). https://doi.org/10.1038/nrrheum.2014.47
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2014.47
This article is cited by
-
Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain?
Pain and Therapy (2024)
-
Functional ability in knee osteoarthritis: role of neuropathic pain and central sensitization
Egyptian Rheumatology and Rehabilitation (2023)
-
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies
Nature Reviews Rheumatology (2023)
-
Supraspinal neuroinflammation and anxio-depressive-like behaviors in young- and older- adult mice with osteoarthritis pain: the effect of morphine
Psychopharmacology (2023)
-
Pathological Characteristics of Monosodium Iodoacetate-Induced Osteoarthritis in Rats
Tissue Engineering and Regenerative Medicine (2023)